Home – CDMO Solutions | Our Approach | Research and innovation
Always innovating to advance cell and gene therapy
OXB is committed to advancing the field of cell and gene therapy to bring life changing treatments to patients with high unmet medical need. We have a dedicated innovation department seeking to improve the quantity, quality and cost of viral vectors to enable greater benefit to patients.
We have scientists and process specialists who are focused solely on research and development to deliver new technologies, optimised manufacturing processes and next-generation viral vector platforms. This commitment ensures that we are not only advancing our own capabilities but also helping our partners bring transformative therapies to patients faster and more efficiently.
Our approach to innovation
Innovation at OXB is driven by a commitment to scientific excellence, operational efficiency, and client-centric solutions.
Our approach includes:
Collaborative research
Partnering with leading academic institutions and industry experts to explore new technologies and methodologies.
Process optimization
Continuously refining our manufacturing processes to enhance scalability, reduce costs, and improve product quality.
Regulatory excellence
Navigating complex regulatory landscapes to ensure compliance and facilitate timely product development.
A proven track record of breakthroughs
For over 30 years, OXB has consistently demonstrated its ability to translate science into impact:
First-in-class therapies that change lives
OXB’s LentiVector™ platform underpinned the world’s first approved CAR-T cell therapy, delivering a treatment that has transformed the lives of patients with otherwise untreatable cancers. OXB’s vectors were also the first to be administered directly into humans for brain and eye gene therapy.
Research that shapes regulatory pathways
Our scientists are not only innovating in the lab but also working with regulators and industry bodies to advance CMC and manufacturing requirements on behalf of clients. By generating new data and proposing streamlined approaches, we are helping to shorten development timelines and improve patient access to advanced therapies worldwide.
Novel platform technologies to drive efficiency
We have pioneered new approaches to vector development, including the TetraVecta™ system for lentiviral vectors, which increases efficiency and productivity, and a dual plasmid system for AAV manufacturing, simplifying production and enabling more robust scalability.
Strategic collaborations to accelerate science
We have forged long-term partnerships with global Industry leaders such as Boehringer Ingelheim, Novartis, Cabaletta Bio, and Orchard Therapeutics. These collaborations combine our platform expertise with our partners’ therapeutic innovation, resulting in the advancement of life-changing treatments across oncology, rare diseases, and infectious diseases.
Current research and development focus
OXB takes a practical, solution-driven approach to innovation, prioritising research that directly advances the development and delivery of cell and gene therapies for our partners.
Taking novel therapies from discovery to commercialisation
Lentiviral platform optimisation and analytics
Continuous evolution of the LentiVector™ platform to improve vector design, potency, and safety, alongside advanced analytical characterisation to ensure robustness from clinical development through to commercial manufacturing.
AAV productivity and capsid quality
Development of novel process and engineering strategies, including dual-plasmid transfection, to enhance AAV yields and increase the proportion of full capsids. Complementary analytical studies provide deeper insight into full, intermediate, and empty capsids, supporting both product quality and therapeutic performance.
Manufacturing scale-up and consistency
Translation of laboratory innovations into GMP-compliant, commercial-scale processes across upstream and downstream manufacturing. The focus is on achieving reproducible quality, cost-effective production, and supply readiness for late-stage and marketed therapies.
Read our latest research and publication
Efficient In Vivo Generation of CAR T Cells using a Retargeted Fourth-Generation Lentiviral Vector
View details >Shaping the future of cell and gene therapy talent
We know how important it is to support the next generation of scientists, which is why OXB leads the Advanced Bioscience of Viral Products (ABViP) programme, a BBSRC-funded Collaborative Training Partnership doctoral training programme, in collaboration with the University of Oxford and University College London. The program addresses the acute skills shortage in viral vector development – a critical need for advancing future gene therapies.
